CHMP grants positive opinion for new indication of Clovis Oncology’s Rubraca®▼ (rucaparib)
Clovis Oncology announced the EU’s CHMP has adopted a positive opinion recommending an additional indication to include rucaparib as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. December 13, 2018